DUBLIN --(BUSINESS WIRE)--Sep. 16, 2026-- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company’s Board of Directors (the Board). Ms. Whitaker is a seasoned biopharmaceutical executive and experienced board director who brings
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Narcolepsy and Idiopathic Hypersomnia in Addition to Schizophrenia and Bipolar I Disorder — — Stage One Submission Period Runs From Sept. 11, 2026 Through Oct.
– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy – – At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue, Cognition and
DUBLIN --(BUSINESS WIRE)--Jul. 28, 2026-- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company’s investor relations website at
DUBLIN --(BUSINESS WIRE)--Jul. 14, 2026-- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST) on Tuesday, July 28, 2026 to discuss the company’s second quarter financial results. The webcast player and accompanying slides may be accessed
— First Long-Term Study of an Orexin 2 Receptor Agonist to Demonstrate Sustained Clinically Meaningful Improvements in Wakefulness and Excessive Daytime Sleepiness for Up to Nine Months in Narcolepsy Type 1 and Type 2 — — Improvements in Patient-Reported Cognition and Fatigue Were Also Sustained —